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Abstract
Background: This systematic review and meta-analysis investigates the efficacy and safety of clonidine as a
sedative in critically ill patients requiring invasive mechanical ventilation.
Methods: We performed a comprehensive search of MEDLINE, EMBASE, CINAHL and the Cochrane trial registry. We
identified RCTs that compared clonidine to any non-clonidine regimen in critically ill patients, excluding neonates,
requiring mechanical ventilation. The GRADE method was used to assess certainty of evidence.
Results: We included eight RCTs (n = 642 patients). In seven of the trials clonidine was used for adjunctive rather
than stand-alone sedation. There was no difference in the duration of mechanical ventilation (mean difference (MD)
0.05 days, 95% confidence interval (CI) = -0.65 to 0.75, I2 = 86%, moderate certainty), ICU mortality (relative risk (RR) 0.
98, 95% CI = 0.51 to 1.90, I2 = 0%, low certainty), or ICU length of stay (MD 0.04 days, 95% CI = -0.46 to 0.53, I2 = 16%,
moderate certainty), with clonidine. There was a significant reduction in the total dose of narcotics (standard mean
difference (SMD) -0.26, 95% CI = -0.50 to -0.02, I2 = 0%, moderate certainty) with clonidine use. Clonidine was
associated with increased incidence of clinically significant hypotension (RR 3.11, 95% CI = 1.64 to 5.87, I2 = 0%,
moderate certainty).
Conclusions: Until further RCTs are performed, data remains insufficient to support the routine use of clonidine as
a sedative in the mechanically ventilated population. Clonidine may act as a narcotic-sparing agent, albeit with an
increased risk of clinically significant hypotension.
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Background
Critically ill patients requiring invasive mechanical venti-
lation (IMV) usually require sedation to minimize dis-
comfort, reduce the risks of self-injury and facilitate care
[1, 2]. Randomized controlled trials (RCTs) have demon-
strated clear benefits of minimizing sedation in this popu-
lation, such as a reduction in the duration of mechanical
ventilation [3, 4], shorter length of stay in the intensive
care unit (ICU) [4–6] and improved overall survival [6].
Typical sedatives used in patients requiring IMV include
propofol, benzodiazepines and more recently, dexmedetomi-
dine [7]. Although propofol has a rapid onset of action and
provides timely recovery after discontinuation, it can cause
clinically significant hypotension [8]. Benzodiazepines may
increase the risk of ICU-related delirium and cause over-
sedation due to drug accumulation, prolonging the duration
of IMV [9]. Compared to benzodiazepines, dexmedetomi-
dine reduces the incidence of delirium and the duration of
IMV [10–12], but is not widely available due to cost.
Clonidine stimulates pre-synaptic alpha-2 adrenore-
ceptors within the brainstem, decreasing norepinephrine
release while enhancing parasympathetic activity. The
sedative, analgesic and anxiolytic effects of clonidine
may be due to its effects on the locus coeruleus [13].
Evidence supporting the use of clonidine as a sedative in
the critically ill requiring IMV remains scarce. One re-
cent systematic review on the efficacy of alpha-2 ago-
nists for sedation in the pediatric critically ill population
included three RCTs using clonidine, but did not pool
estimates. They concluded that robust evidence was
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lacking for the use of clonidine as a sedative in the
pediatric critically ill population [14]. A Cochrane meta-
analysis that assessed the efficacy of alpha-2 agonists on
the quality of sedation in ventilated critically ill patients
did not include any studies on clonidine [15]. The 2013
Pain, Agitation, and Delirium guidelines make no rec-
ommendation on the use of clonidine [16]. The objective
of our systematic review is to summarize the available
RCT evidence on the use of clonidine as a sedative in
the ICU in order to better inform clinical practice.
Methods
Data sources and searches
We performed a comprehensive search of MEDLINE,
Excerpta Medica database (EMBASE), Cumulative Index
to Nursing and Allied Health Literature (CINAHL), and
the Cochrane trial registry from inception until March
2016 (Appendix 1). No date or language restrictions were
applied. Two reviewers independently screened all refer-
ences for inclusion and a third party resolved discrepan-
cies. We identified unpublished and ongoing trials using
the World Health Organization International Clinical Tri-
als Registry Platform (WHO ICTRP) and clinicaltrials.gov
databases. Conference proceedings for the Society of
Critical Care Medicine (SCCM), Canadian Critical Care
Society, the European Society of Intensive Care Medicine
(ESICM), and the American Thoracic Society (ATS) were
screened in duplicate for the last 2 years.
Study selection
No methodological quality restrictions were imposed.
Although non-randomized prospective studies were
identified in the initial search, a sufficient number of
RCTs were identified such that only RCT data were sub-
sequently analyzed and reported. Eligible studies were
RCTs reporting the use of clonidine, either as a primary
sedative or adjunctive agent, compared to any non-
clonidine sedative regimen, in patients who required
IMV. Studies that used clonidine for any indication
other than sedation (e.g. opioid withdrawal) were ex-
cluded. We excluded studies enrolling only neonates and
those in which clonidine was administered by a route
other than enteral or intravenous (IV).
We included studies that reported any of our a priori out-
comes, namely the duration of mechanical ventilation, dur-
ation of non-invasive ventilation (NIV), all-cause mortality,
duration of sedative infusion, dose of benzodiazepines or
narcotics used during ICU stay, the level of sedation, inci-
dence of withdrawal from other sedatives, incidence of de-
lirium, and ICU and hospital length of stay. Adverse events
were also captured, including clinically significant bradycar-
dia and hypotension requiring intervention, clonidine with-
drawal symptoms (rebound hypertension), the unplanned
removal of support lines and unplanned extubation.
Data extraction and quality assessment
Data extraction was performed independently and in du-
plicate using predefined data abstraction forms. A third
reviewer resolved disagreements when necessary.
Independently and in duplicate, two reviewers assessed
the risk of bias (ROB) for each outcome of individual studies
using the Cochrane ROB tool [17]. The ROB was judged to
be “low risk,” “high risk” or “unclear risk” within the follow-
ing domains: sequence generation, allocation sequence con-
cealment, blinding, selective outcome reporting and other
bias. We assessed the overall certainty of evidence using the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) method [18] for each outcome in-
dependently. Disagreements for ROB and GRADE assess-
ments were resolved by discussion and consensus.
Data analysis
Results are presented as relative risk (RR) with 95% con-
fidence interval (CI) for dichotomous outcomes and as
mean difference (MD) or standardized mean difference
(SMD) for continuous outcomes with 95% CI. Meta-
analyses were conducted on pooled outcomes using Re-
view Manager 5.3. Random effects model analysis was
performed for all outcomes and study weights were mea-
sured using the inverse variance strategy, in the method
of DerSimonian and Laird [19].
Heterogeneity was assessed using the chi-squared test
for homogeneity, and the I2 statistic [20]; I2 greater than
50% was considered significant heterogeneity. The Egger
test was not performed as less than ten trials were identi-
fied [21]. We used the GRADEPro guideline development
tool to formulate GRADE evidence profiles [22].
Outcomes
Primary and secondary outcomes of interest were described
a priori in a separately published protocol [23]. As per the
predefined protocol, outcomes were pooled across studies
and described narratively if pooling was not possible. Sub-
group and sensitivity analyses were not conducted due to
the limited number of trials identified per outcome.
Results
Study identification
Of an initial 792 citations, 33 underwent full text review.
After excluding a further 25 studies, a total of eight RCTs
met inclusion criteria [24–31]. In addition, we identified
three ongoing RCTs (NCT01139996, NCT02509273,
NCT01876355) (Fig. 1).
Study characteristics
A detailed description of the included trials is presented
in Table 1. Four trials enrolled children [24–26, 29] and
four enrolled adults [27, 28, 30, 31]. Clonidine was ad-
ministered intravenously in six trials [24, 26–30] and via
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the enteral route in two trials [25, 31]. The trials that
used intravenous clonidine took place in Brazil, the
United Kingdom, Germany, India and Italy [24, 26–30],
respectively. The doses of clonidine varied considerably,
with enteral clonidine doses ranging from 0.1 to 0.2 mg
every 8 hours [31] to 5 μg/kg every 6 hours [25]. The
doses for IV continuous clonidine infusions ranged from
0.88 to 3 μg/kg/hour [26–30] and some studies used an
initial bolus dose [26, 28, 30]. One study used intermit-
tent IV doses of clonidine at 5 μg/kg every 8 hours [24].
Most trials used clonidine as an adjunctive agent added
to an established sedative regimen, generally consisting
of a benzodiazepine and/or an opioid [24–26, 29–31]. A
single trial used clonidine as a stand-alone agent, com-
pared to dexmedetomidine [27].
Risk of bias
ROB was reported using the Cochrane ROB tool for
each individual study (Appendix 2) [17]. Overall, two tri-
als were at low ROB [25, 29] and six trials at high ROB
[24, 26–28, 30, 31]. Of the high ROB trials, one did not
specify blinding details and had a high risk of attrition
bias (33% of patients in the clonidine group were lost to
follow-up) [31]. Another trial had a high risk of selection
bias, as study investigators did not specify whether the
envelopes used for randomization were sealed or opaque
[30]. One did not blind patients or caregivers and ex-
cluded 21 of 180 patients post-randomization [28]. One
was an open-label study, with associated risks of per-
formance and detection bias [27]. Four did not describe
allocation concealment [24, 26, 28, 31].
Certainty of evidence
Each outcome was rated on the certainty in effect esti-
mates using the GRADE approach (Table 2).
Pooled outcomes
Duration of mechanical ventilation
The duration of mechanical ventilation was similar for pa-
tients receiving clonidine and those in the non-clonidine
group (six studies, n = 417 patients, MD 0.05 days, 95% CI
-0.65 to 0.75, I2 = 86%, moderate certainty) [24, 25, 27–30]
(Fig. 2). There was insufficient data to comment on the
use and duration of NIV.
Fig. 1 Flow diagram depicting a summary of the search and selection process. CINAHL Cumulative Index to Nursing and Allied Health Literature,
EMBASE Excerpta Medica database, RCTs randomized controlled trials
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All cause mortality
There was no difference in ICU mortality (five studies,
n = 383 patients, RR 0.98, 95% CI = 0.51 to 1.90, I2 = 0%,
low certainty) [24, 26–28, 30] (Appendix 3), or hospital
mortality (two studies, n = 139 patients, RR 0.37, 95%
CI = 0.08 to 1.76, I2 = 0%, moderate certainty) [25, 29]
(Appendix 4) between the clonidine and the non-
clonidine group.
Other sedatives, analgesics and sedation parameters
There was no difference in the duration of sedative infu-
sions (three studies, 245 patients, MD -0.28 days, 95%
CI = -0.91 to 0.34, I2 = 82%, low certainty) [25–27] (Ap-
pendix 5), or total dose of benzodiazepines (four studies,
264 patients, SMD 0.02, 95% CI = -0.34 to 0.39, I2 = 55%,
moderate certainty) [25, 27, 29, 31] (Appendix 6) be-
tween the clonidine and non-clonidine groups. The total
dose of narcotics was significantly reduced in the cloni-
dine group compared to the non-clonidine group (four
studies, 264 patients, standard mean difference (SMD)
-0.26, 95% CI = -0.50 to -0.02, I2 = 0%, moderate cer-
tainty) [25, 27, 29, 31] (Fig. 3).
Four RCTs reported the level of sedation achieved. Two
RCTs used a sedation scoring system and reported this as a
continuous outcome, which allowed pooling [25, 29]. Ana-
lysis showed no difference in the level of sedation achieved
in the clonidine compared to the non-clonidine group (two
studies, 139 patients, SMD -0.28, 95% CI = -0.61 to 0.06,
I2 = 0%, moderate certainty) [25, 29] (Appendix 7).
Withdrawal from other sedatives
Three RCTs reported the incidence of withdrawal from
other sedatives [24–26]. This was defined using a with-
drawal diagnostic tool, namely the Finnegan score [24],
the Withdrawal Assessment Tool 1 [25] and an 11-point
assessment for abnormal behaviors [26]. Overall, there
was no significant difference in the incidence of with-
drawal from other sedatives between groups (three stud-
ies, 244 patients, RR 0.91, 95% CI = 0.67 to 1.23, I2 = 0%,
low certainty) [24–26] (Appendix 8). There was insuffi-
cient data to comment on the incidence of delirium.
ICU and hospital length of stay
There was no difference in the ICU length of stay (six trials,
473 patients, MD 0.04 days, 95% CI = -0.46 to 0.53, I2=
16%, moderate certainty) [25–30] (Appendix 9) or hospital
length of stay (three studies, 245 patients, MD -0.66, 95%
CI = -2.18 to 0.87, I2= 52%, very low certainty) [25–27] (Ap-
pendix 10) between the clonidine and non-clonidine groups.
Adverse events
An increased incidence of clinically significant hypotension
requiring intervention was evident in the clonidine com-
pared to the non-clonidine group (four studies, 404 pa-
tients, RR 3.11, 95% CI = 1.64 to 5.87, I2 = 0%, moderate
certainty) [25–28] (Fig. 4). Two studies defined clinically
significant hypotension as any decrease in blood pressure
requiring intervention, such as holding or lowering the dose
of clonidine, or requiring administration of intravenous
Fig. 2 Forest plot comparing the duration of mechanical ventilation between the clonidine group and the non-clonidine group (control). Results
are depicted using a random effects model with mean difference and 95% confidence intervals
Fig. 3 Forest plot comparing the dose of narcotics used between the clonidine group and the non-clonidine group (control). Results are depicted
using a random effects model with standard mean difference and 95% confidence intervals
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fluids [25, 26]. One study used a systolic blood pressure
cutoff of 80 mmHg, diastolic blood pressure cutoff of
50 mmHg, or change in baseline blood pressure of >30% as
criteria for clinically significant hypotension [27]. Another
study defined it as a blood pressure <60 mmHg (unclear if
this is mean arterial pressure, systolic or diastolic blood
pressure), or any hypotension requiring intervention with a
vasopressor or inotrope [28].
There was no difference in the incidence of clinically signifi-
cant bradycardia requiring intervention (four studies, 404 pa-
tients, RR 1.34, 95% CI = 0.45 to 3.98, I2= 45%, low certainty)
[25–28] (Appendix 11) or the incidence of rebound hyperten-
sion (two studies, 195 patients, RR 5.37, 95% CI = 0.63 to
45.49, I2= 0%, low certainty) [26, 27] (Appendix 12). None of
the included studies reported on the incidence of unplanned
removal of central IV lines or unplanned extubation.
Discussion
We found no significant difference in the duration of IMV,
ICU mortality, duration of sedation infusion or ICU length
of stay between the clonidine and non-clonidine groups.
However, a high degree of clinical heterogeneity limits the
interpretation of these results. Included studies were het-
erogeneous with regards to patient age (adults and pediatric
patients), and types of patients, including medical, post-
operative or mixed groups. Notably, the patients in two of
the trials were post-operative and thus mechanically venti-
lated for only a brief period (mean < 72 hours) [28, 30],
making it less likely that these studies would demonstrate
significant differences in the duration of IMV. Further, clo-
nidine dosing and route of administration, as well as the
comparators used, varied across trials. This may have con-
tributed to a high degree of statistical heterogeneity for
some outcomes. Unfortunately, due to the scarcity of evi-
dence, a priori planned subgroup analyses attempting to ex-
plain this heterogeneity was not possible.
The level of sedation achieved did not differ significantly
between the clonidine and non-clonidine groups. How-
ever, pooled analysis was limited as the reporting mecha-
nisms for this outcome varied amongst the trials. Two
trials used score cutoffs from different sedation scoring
systems [25, 29], while two other trials reported the time
spent in a predefined adequate sedation range [26, 27].
Perhaps the most important role of clonidine is as an ad-
junctive or sedative sparing agent. This is supported by the
finding that clonidine reduces the total dose of narcotics re-
quired. This is consistent with previous studies in the peri-
operative setting suggesting that clonidine may be effective
as an analgesic adjunct to opioids by decreasing the overall
narcotic requirements [32]. The mechanism may be due to
the modest anti-nociceptive effects of clonidine via stimula-
tion of central post-synaptic alpha-2 adrenoreceptors in the
spinal cord and brain stem nuclei [32]. These results support
the potential role of clonidine as a narcotic-sparing sedative.
The role of clonidine as a stand-alone sedative remains
unclear. In this review, only one trial used clonidine as a
stand-alone sedative, compared to dexmedetomidine [27].
Less patients in the clonidine group achieved target sed-
ation. This was largely due to concerns with hypotension,
which limited the ability to increase and optimize the clo-
nidine dose. The higher incidence of clinically significant
hypotension with clonidine use is also reflected in this re-
view. However, before definitive conclusions can be drawn,
further dosing studies using variable route and delivery
methods of clonidine are needed, as there is currently no
standard regimen for clonidine administration. These fac-
tors may significantly impact the incidence of hypotension
with clonidine use. Further, although clonidine is a signifi-
cantly cheaper alternative to dexmedetomidine, dedicated
cost-effectiveness analysis, taking into consideration drug
efficacy, adverse effects and cost would better inform the
clinician on the drugs’ practical applicability.
This systematic review has several strengths. We per-
formed a comprehensive literature search, used the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines [33] and established and published a
protocol [23]. Data abstraction was performed in duplicate
and study authors were contacted to address missing
data. Multiple clinically relevant outcomes were defined a
priori and included in the analysis. Also, using GRADE
methodology, we were able to report the certainty in the
overall estimates of effect for our outcomes of interest.
Fig. 4 Forest plot comparing the incidence of clinically significant hypotension requiring intervention between the clonidine group and the
non-clonidine group (control). Results are depicted using a random effects model with relative risk ratio and 95% confidence intervals
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However, there were several limitations to our ana-
lyses. There was substantial clinical heterogeneity, limit-
ing direct comparisons between groups. The ROB was
also moderately high across trials, affecting the validity
of individual outcomes. These factors were accounted
for in our GRADE assessments, resulting in many out-
comes with low certainty in the pooled estimates. Fur-
ther, the number of studies was insufficient to allow for
meaningful subgroup and sensitivity analyses.
Conclusions
Based on moderate- to low-certainty evidence, the use of
clonidine did not significantly change the duration of
mechanical ventilation, although it did result in a signifi-
cantly decreased requirement for narcotics, however with
an increased incidence of clinically significant hypotension.
Until further large-scale RCTs are performed, data remains
insufficient to support the routine use of clonidine as a
sedative, either stand-alone or adjunctive, in the mechanic-
ally ventilated population.
Appendix 1
The MEDLINE search strategy, including search terms
and relevant Medical Subject Headings
Appendix 2
Risk of bias assessment for each trial using the Cochrane
risk of bias tool. The green symbol represents low risk
of bias and the red symbol represents high risk of bias.
The yellow symbol represents an unclear risk of bias.
Appendix 3
Forest plot comparing the incidence of mortality in the
intensive care unit between the clonidine group and the
non-clonidine group (control). Results are depicted
using a random effects model with relative risk ratio and
95% confidence intervals.
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Appendix 4
Forest plot comparing the incidence of mortality during
the hospital stay between the clonidine group and the
non-clonidine group (control). Results are depicted
using a random effects model with relative risk ratio and
95% confidence intervals.
Appendix 5
Forest plot comparing the duration of sedative infusions
between the clonidine group and the non-clonidine
group (control). Results are depicted using a random ef-
fects model with mean difference and 95% confidence
intervals.
Appendix 6
Forest plot comparing the dose of benzodiazepines used
between the clonidine group and the non-clonidine
group (control). Results are depicted using a random ef-
fects model with standard mean difference and 95% con-
fidence intervals.
Appendix 7
Forest plot comparing the level of sedation between the
clonidine group and the non-clonidine group (control).
Results are depicted using a random effects model with
standard mean difference and 95% confidence intervals.
Appendix 8
Forest plot comparing the incidence of withdrawal from
other sedatives between the clonidine group and the
non-clonidine group (control). Results are depicted
using a random effects model with relative risk ratio and
95% confidence intervals.
Appendix 9
Forest plot comparing the duration of stay in the inten-
sive care unit between the clonidine group and the non-
clonidine group (control). Results are depicted using a
random effects model with mean difference and 95%
confidence intervals.
Appendix 10
Forest plot comparing the duration of stay in the hospital
between the clonidine group and the non-clonidine group
(control). Results are depicted using a random effects
model with mean difference and 95% confidence intervals.
Appendix 11
Forest plot comparing the incidence of clinically signifi-
cant bradycardia between the clonidine group and the
non-clonidine group (control). Results are depicted
using a random effects model with relative risk ratio and
95% confidence intervals.
Wang et al. Critical Care  (2017) 21:75 Page 9 of 11
Appendix 12
Forest plot comparing the incidence of rebound hyper-
tension between the clonidine group and the non-cloni-
dine group (control). Results are depicted using a
random effects model with relative risk ratio and 95%
confidence intervals.
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